Dr. Ibrahim Aldoss, MD
Claim this profileCity of Hope Medical Center
Expert in Childhood Cancer
Expert in Acute Lymphoblastic Leukemia
15 reported clinical trials
30 drugs studied
Area of expertise
1Childhood Cancer
Global LeaderCD19 positive
Stage IV
BCR-ABL1 positive
2Acute Lymphoblastic Leukemia
Global LeaderCD19 positive
Stage IV
BCR-ABL1 positive
Affiliated Hospitals
Clinical Trials Ibrahim Aldoss, MD is currently running
CAR T Cell Therapy
for Acute Lymphoblastic Leukemia
This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of B-cell acute lymphoblastic leukemia.
Recruiting1 award Phase 1
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
More about Ibrahim Aldoss, MD
Clinical Trial Related1 year of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Ibrahim Aldoss, MD has experience with
- Venetoclax
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
- Flotetuzumab
- Blinatumomab
- C10403
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
Breakdown of trials Ibrahim Aldoss, MD has run
Childhood Cancer
Acute Lymphoblastic Leukemia
Lymphoma
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ibrahim Aldoss, MD specialize in?
Ibrahim Aldoss, MD focuses on Childhood Cancer and Acute Lymphoblastic Leukemia. In particular, much of their work with Childhood Cancer has involved CD19 positive patients, or patients who are Stage IV.
Is Ibrahim Aldoss, MD currently recruiting for clinical trials?
Yes, Ibrahim Aldoss, MD is currently recruiting for 8 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Ibrahim Aldoss, MD has studied deeply?
Yes, Ibrahim Aldoss, MD has studied treatments such as Venetoclax, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Flotetuzumab.
What is the best way to schedule an appointment with Ibrahim Aldoss, MD?
Apply for one of the trials that Ibrahim Aldoss, MD is conducting.
What is the office address of Ibrahim Aldoss, MD?
The office of Ibrahim Aldoss, MD is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.